Walgreens (WBA) and Prothena (PRTA) announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. As part of the collaboration, Walgreens will leverage its national footprint, portfolio of industry-leading healthcare companies and compliance framework to match patient populations to this Prothena clinical trial for PRX012, which has been granted Fast Track designation by the U.S. Food and Drug Administration
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on WBA:
- Walgreens Boots Alliance price target lowered to $46 from $47 at Deutsche Bank
- Walgreens Boots Alliance price target lowered to $37 from $39 at UBS
- Walgreens Boots Alliance price target lowered to $40 from $42 at Truist
- Walgreens Boots Alliance Inc. Earnings Update: Did it Beat Estimate Forecasts?
- Walgreens In the Green on Q2 Beat